HALO -.49 to 36.88, I recently joined you with a small position. Q3 EPS of $0.75 beat estimates. Analysts are expecting 38% EPS growth in 2024, although that seems aggressive. The stock is way down from its 52wk high of $57+ and recent weakness may be due to tax loss selling pressure. I think it's a good candidate for a January bounce followed by solid gains for the full year. I'm accumulating shares.
briefing -
Halozyme Therapeutics beats by $0.04, reports revs in-line; guides FY23 EPS above consensus, revs in-line (35.26 -0.32) :
Reports Q3 (Sep) earnings of $0.75 per share, excluding non-recurring items, $0.04 better than the FactSet Consensus of $0.71; revenues rose 3.4% year/year to $216 mln vs the $216.08 mln FactSet Consensus.
Co issues guidance for FY23, sees EPS of $2.70-$2.80 vs. $2.64 FactSet Consensus, up from prior guidance of $2.65-$2.75; sees FY23 revs of $825-$845 mln vs. $830.22 mln FactSet Consensus.
